NorthWest Biotherapeutics Inc (NWBO)

[kabunushi]

If you are asking whether I think these results are good enough for approval, I say yes, for sure. Blended mOS of 23 implies treatment 25 which is very solid improvement over SOC of 19 or less. Correct me if I'm wrong but treatments with far worse safety profiles have been approved for less improvement that than this.

As for "AVI77 who nailed it.", as I recall he said there's no way mOS is more than 20 months. That's a fairly big miss vs 23 months in my book - large enough to make the difference between likely approval vs likely non-approval. Anyway I predict approval based on the tail results, not just on mOS, which I'm sure you'll say is not stat sig. Actual clinical demand for this improved chance of surviving a lot longer will push this through approval in any case, imo.